Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Cut to $154.00

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target dropped by analysts at Robert W. Baird from $160.00 to $154.00 in a research note issued on Thursday, Benzinga reports. The firm presently has an “outperform” rating on the specialty pharmaceutical company’s stock. Robert W. Baird’s price target would indicate a potential upside of 39.68% from the company’s previous close.

Other analysts have also issued reports about the stock. StockNews.com lowered shares of Jazz Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 5th. Needham & Company LLC cut their price target on shares of Jazz Pharmaceuticals from $222.00 to $210.00 and set a “buy” rating for the company in a research report on Thursday, June 20th. UBS Group cut their price target on shares of Jazz Pharmaceuticals from $117.00 to $113.00 and set a “neutral” rating for the company in a research report on Tuesday, July 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $180.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, April 10th. Finally, Morgan Stanley lowered their price objective on shares of Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating for the company in a research note on Friday, July 12th. Three equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $185.43.

Jazz Pharmaceuticals Stock Down 1.8 %

Shares of NASDAQ:JAZZ opened at $110.25 on Thursday. Jazz Pharmaceuticals has a 52-week low of $99.06 and a 52-week high of $146.70. The firm has a fifty day moving average of $107.47 and a 200 day moving average of $114.15. The firm has a market capitalization of $6.95 billion, a PE ratio of 22.73, a price-to-earnings-growth ratio of 1.73 and a beta of 0.58. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.90 and a current ratio of 2.27.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.53 by ($1.55). Jazz Pharmaceuticals had a return on equity of 27.86% and a net margin of 8.61%. The company had revenue of $901.98 million during the quarter, compared to analysts’ expectations of $938.99 million. As a group, research analysts anticipate that Jazz Pharmaceuticals will post 15.31 EPS for the current fiscal year.

Insider Activity

In other news, EVP Neena M. Patil sold 5,000 shares of the stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $109.65, for a total transaction of $548,250.00. Following the sale, the executive vice president now owns 36,629 shares in the company, valued at $4,016,369.85. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 4.20% of the company’s stock.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of institutional investors have recently made changes to their positions in JAZZ. Allspring Global Investments Holdings LLC boosted its holdings in Jazz Pharmaceuticals by 0.6% in the first quarter. Allspring Global Investments Holdings LLC now owns 16,082 shares of the specialty pharmaceutical company’s stock worth $1,937,000 after purchasing an additional 99 shares during the last quarter. Waterfront Wealth Inc. increased its holdings in Jazz Pharmaceuticals by 1.2% in the 4th quarter. Waterfront Wealth Inc. now owns 8,633 shares of the specialty pharmaceutical company’s stock valued at $1,062,000 after acquiring an additional 103 shares during the last quarter. ProShare Advisors LLC increased its holdings in Jazz Pharmaceuticals by 1.4% in the 1st quarter. ProShare Advisors LLC now owns 7,439 shares of the specialty pharmaceutical company’s stock valued at $896,000 after acquiring an additional 105 shares during the last quarter. Prime Capital Investment Advisors LLC increased its holdings in Jazz Pharmaceuticals by 4.3% in the 4th quarter. Prime Capital Investment Advisors LLC now owns 2,646 shares of the specialty pharmaceutical company’s stock valued at $325,000 after acquiring an additional 108 shares during the last quarter. Finally, Ontario Teachers Pension Plan Board increased its holdings in Jazz Pharmaceuticals by 0.4% in the 4th quarter. Ontario Teachers Pension Plan Board now owns 29,749 shares of the specialty pharmaceutical company’s stock valued at $3,659,000 after acquiring an additional 108 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.